Study to Evaluate Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy

Study Identifier:
22183
ClinicalTrials.gov Identifier:
NCT00528268
EudraCT Identifier:
N/A
EU CT Number:
N/A
Sponsor:
University of Utah
Study Complete

Study Details

Medical Condition
  • All Spinal Muscular Atrophies
Study Drug
  • Drug: Sodium phenylbutyrate
Date
Jul 2007 - Dec 2013
Patient Requirements
Sex: Female & Male
Age: 1 Day - 6 Months
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • Laboratory documentation of homozygous absence of SMN1 exon 7.
  • Confirmation of no more than 3 SMN2 copies for cohort 1; no more than 4 copies for cohort 2.
  • Family history of affected sibling with SMA type I for cohort 1 and SMA type II for cohort 2.
  • Age ≤ 3 months, cohort 1; Age ≤ 6 months, cohort 2.
  • Written informed consent of parents/guardian.
  • Laboratory results demonstrating normal values for age.
Exclusion Criteria
  • Evidence of hepatic insufficiency, renal insufficiency, edema with sodium retention, known seizure disorder, urea cycle disorder, cardiac arrhythmia, congenital heart defect, hypertension, significant central nervous system (CNS) impairment, or neurodegenerative or neuromuscular disease other than SMA.
  • History of allergy/sensitivity to sodium phenylbutyrate (NaPB).
  • Use of NaPB within 30 days of study entry.
  • Serious illness requiring hospitalization ≤ 14 days prior to study entry.
  • Use of medications intended for the treatment of SMA including riluzole, valproic acid, hydroxyurea, oral use of albuterol, NaPB, butyrate derivatives, creatine, growth hormone, anabolic steroids, probenecid, oral or parenteral use of corticosteroids at entry, or agents anticipated to increase or decrease muscle strength or agents with presumed histone deacetylase (HDAC) inhibition within 30 days prior to study entry.
  • Unwillingness to travel for study assessments.

Protocol Summary

In this single-center trial, we will evaluate the effects of NaPB on presymptomatic Spinal Muscular Atrophy (SMA) type I (cohort 1)and presymptomatic SMA type II (cohort 2) infants. A variety of outcome measures will be performed at each study visit to follow the course of the disease. Total duration of the study for type I infants will be 18 months, for type II infants, 24 months.

Trial Locations

Location
Status
Location
University of Utah
Salt Lake City, Utah, United States, 84132
Status
N/A

Contact Cure SMA

User Information

If you have general questions regarding clinical trials or would like to be added to the Cure SMA mailing list to receive communications regarding future registries, studies, or clinical trials in SMA, please fill out the form below. Fields marked with an asterisk (*) are mandatory.

  • Disability Advocate who does not have SMA
  • I am a healthcare provider
  • I am a researcher
  • I have no direct connection to SMA
  • I have SMA
  • I lost a child to SMA
  • My child has SMA
  • Someone close to me has/had SMA
  • Australia
  • Belgium
  • Brazil
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Estonia
  • France
  • Germany
  • Greece
  • Hong Kong
  • Hungary
  • India
  • Ireland
  • Israel
  • Italy
  • Japan
  • Lebanon
  • Malaysia
  • Mexico
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Republic of Korea
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.